Inhibikase Therapeutics, Inc.IKTEarnings & Financial Report
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel disease-modifying therapies for neurodegenerative disorders including Parkinson's disease. It advances pipeline candidates through preclinical and clinical studies to address unmet medical needs and improve patient outcomes worldwide.
IKT Q4 FY2025 Key Financial Metrics
Revenue
$1.0M
Gross Profit
N/A
Operating Profit
$-13.8M
Net Profit
$-12.7M
Gross Margin
N/A
Operating Margin
-1323.3%
Net Margin
-1223.3%
YoY Growth
N/A
EPS
$-0.10
Inhibikase Therapeutics, Inc. Q4 FY2025 Financial Summary
Inhibikase Therapeutics, Inc. reported revenue of $1.0M for Q4 FY2025, with a net profit of $-12.7M (down 5.0% YoY) (-1223.3% margin).
Key Financial Metrics
| Total Revenue | $1.0M |
|---|---|
| Net Profit | $-12.7M |
| Gross Margin | N/A |
| Operating Margin | -1323.3% |
| Report Period | Q4 FY2025 |
Inhibikase Therapeutics, Inc. Annual Revenue by Year
Inhibikase Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.0M).
Inhibikase Therapeutics, Inc. Quarterly Revenue & Net Profit History
Inhibikase Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.0M | — | $-12.7M | -1223.3% |
| Q3 FY2025 | $0 | — | $-11.9M | N/A |
| Q2 FY2025 | $0 | — | $-9.9M | N/A |
| Q1 FY2025 | $0 | — | $-13.7M | N/A |
| Q4 FY2024 | $0 | — | $-12.1M | N/A |
| Q3 FY2024 | $0 | — | $-5.8M | N/A |
| Q2 FY2024 | $0 | — | $-5.0M | N/A |
| Q1 FY2024 | $0 | — | $-4.6M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.0M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $11.1M | $8.8M | $4.4M | $98.6M | $94.3M | $88.9M | $79.6M | $181.2M |
| Liabilities | $4.3M | $3.7M | $4.9M | $3.7M | $8.6M | $8.8M | $6.7M | $8.3M |
| Equity | $6.8M | $5.1M | $-530591 | $94.9M | $85.7M | $80.1M | $72.9M | $172.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.9M | $-5.1M | $-4.9M | $-5.3M | $-4.1M | $-5.6M | $-10.6M | $-7.5M |